Dx Deal Review 2023

In 2023, the diagnostics sector saw over 430 Dx-related transactions, averaging approximately 110 deals per quarter. USA and North America generally dominated the deal space, with 68% of sellers and 61% of buyers. European engagement was lower, with 24% and 30%...

read more

Pharma Services Overview

Despite concerns around the global political and economic landscape, the biopharmaceutical industry still maintains a favourable mid-to long-term outlook with a promising future for revenues. The industry’s clinical pipeline remains robust, with a growing number of...

read more

Value Creation in the CDMO Market

Contract Development & Manufacturing Organisations (CDMOs) increasingly need to differentiate and establish their competitive advantage to effectively cater to the growing demand and to enhance their profitability. There is a greater demand for CDMOs offering...

read more

Diagnostics

More important than ever, but there’s still a way to go. Just the other week, it was announced that Illumina had acquired GRAIL (subject to approval from the regulators), a company it formed in 2016 and spun out. Illumina retained a 12% stake in the business and has...

read more

Non-Small Cell Lung Cancer (NSCLC)

NSCLC is one of the most active areas of innovation in Oncology, and recent consensus estimates indicate that an additional $20BN of sales could be added in the indication over the next few years.

read more

Deal Making in the Year of Covid-19

In the Spring of 2020, during the early days of the COVID-19 pandemic when there were real fears of a global downturn, PharmaVentures predicted that despite the forthcoming challenges, licensing and partnering would remain steady during 2020. With the year behind us,...

read more

Is Nationalism Transforming the Pharma Manufacturing Map?

The last few years have seen a rise in nationalism and populism across the world. In 2016, the US voted in the populist Donald Trump on his promise to ‘Make America Great Again’. In 2018, Hungary re-elected its national conservative prime minister Viktor Orbán with...

read more

Data Room Structure Guideline

At PharmaVentures, a data room is used as a location to store essential documents that are needed during an M&A or Divestment transaction. It is an essential part of the due diligence process which interested buyers access prior to closing a transaction. We...

read more

The Rise of Gene Therapies in Neurological Diseases

In the recent years, the level of interest in Gene Therapy from both industry and academia has been unparalleled. CNS disorders in particular have gained a lot of attention with a considerable emphasis on neurological targets; and this is especially visible when...

read more

The Upsurgence of Nanotechnology

The term Nanotechnology refers to the domain of science and engineering that is applied to structures and materials that measure only a few billionths of a meter.  The term was coined by Japanese scientist Norio Taniguchi almost 40 years ago, and then popularised...

read more

Industry Insight: Why Size and Timing matter

It’s easy to find trading and M&A multiples for mid and top tier CROs as their financial data are plentiful, often in the public domain and are the subject of discussion both in print and at conferences globally.  Although consolidation in this sector is often...

read more

Reducing Pain for Patients and Dealmakers

Pain management continues to face the dual hurdles of abuse of the most efficacious (opiod based) therapies and the difficulties of developing and commercialising new treatments. This challenging environment presents difficulties both for large pharmaceutical...

read more

Opportunities in Emerging Markets

This presentation (available download on the left-hand side of this page) provides an overview of the EM opportunity, including some analysis of the financial performance of selected EM pharmaceutical industries and respective benchmark valuation metrics....

read more

Co-promotion Deals – Panacea or Poison Pill?

The incidence of co-promotion components in biotechnology/pharmaceutical licensing deals for development products has grown steadily since 1996 according to data from PharmaDeals© V4. In 1996 just 6% of licensing deals retained co-promotion rights or options for...

read more

Antibiotic Resistance, A Global Issue

The growing threat of bacterial resistance is a high priority global issue with 193 countries signing a landmark UN General Assembly declaration calling for coordinated effort in this area. Without urgent action today's routine infections could become killers and the...

read more